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OBJECTIVES: Since 2002, the BRP for medicinal products
claiming ATV requires the evaluation of the therapeutic and
pharmaco-economic value as compared to alternatives. The
study aim was to analyze the effect of ATV and ICER on the
DRD. METHODS: The RIZIV administrative database was used
for extracting all ﬁles claiming ATV submitted between January
2002 and February 2008. ICERs expressed per QALY or per
LYG were pooled. ATV was a binary outcome variable (ATV
either present or absent). The DRD was either positive or nega-
tive. Statistical analysis (logistic regression /backwards elimina-
tion) was performed using SAS EG. The signiﬁcance level was set
at 0.05. Only complete cases were analyzed. RESULTS: A total
of 138 submissions fulﬁlled the criteria. Data were available for
all variables in only 76 (55.1%) cases. ATV and ICER were both
signiﬁcantly (p < 0.01) related with the ﬁnal DRD. The odds of a
positive DRD increase to 9.5-fold if ATV was granted and
decrease to 0.45-fold if the ICER increases €10,000. No signiﬁ-
cant interactions were observed (p > 0.10). CONCLUSIONS:
Based on this sample, our analysis indicates that both ATV and
ICER have a prognostic (but opposite) effect on the ﬁnal DRD in
Belgium. Further investigation should consider the potential
effects of other variables such as budget impact, disease category,
price and others on the DRD.
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OBJECTIVES: The study aim was to investigate the time delays
between market authorization, reimbursement submission and
reimbursement authorization and to analyze whether the type of
submission affects these delays for new products. METHODS:
Data were extracted from the Riziv administrative database. A
total of 613 reimbursement ﬁles were handled between January
1, 2002 and December 31, 2007. The three submission types
were: added (n = 104) or similar (n = 480) therapeutic value or
orphan status (n = 29). The following variables were computed:
TTS = time between market authorization and reimbursement
submission; TSA = time between reimbursement submission and
authorization; TMR = time between market authorization and
reimbursement authorization. Resubmissions of unapproved
claims were excluded to maintain the independency between
ﬁles. All statistical analyses were executed in SAS EG. RESULTS:
The median (25th–75th percentile)delays (in days) were respec-
tively 137 (46–308), 258 (235–294) and 421 (307–633) for
TTS, TSA and TMR. There was no signiﬁcant difference in
TTS (p = 0.11) between submission types: TSA and TMR were
signiﬁcantly longer (p < 0.05) respectively for added value and
orphan submissions as compared to claims for similar value.
CONCLUSIONS: The median delay between marketing autho-
rization and actual reimbursement of new medicines is 421 days
in the 2002–2007 period. However the local applicant needs a
median of 137 days before a reimbursement claim is submitted:
the reimbursement process needs a median of 258 days between
submission and authorization, overestimating the time needed
because it includes any suspension period requested by the appli-
cant during the procedure. There was no signiﬁcant difference in
TTS between submission types indicating that the need for
pharmaco-economic data for added value claims is not jeopar-
dizing TTS. TSA for added value and TMR for orphan submis-
sions were signiﬁcantly longer indicating the more complex
evaluation process which precedes the reimbursement decision.
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OBJECTIVES: Since 2006 physicians have been able to select the
competitive drug acquisition program (CAP) as an alternative
method of acquiring drugs and biologics for in-ofﬁce adminis-
tration under Medicare. This study examines the evolution of
the program from 2006 to present, recounts the legislative and
regulatory program impacts and describes issues that remain
as potential obstacles to widespread provider acceptance.
METHODS: Historic CAP regulatory and legislative guidance
was collected, arranged in order of issuance, abstracted and
analyzed. A timeline illustrating evolutionary program modiﬁca-
tions was constructed. Remaining issues that may deter provider
participation were described and information resources were
compiled. RESULTS: The CAP is a payment model that removes
the drug purchasing function from the physician’s ofﬁce while the
drug administration responsibility remains. Despite intent to
minimize provider ﬁnancial risk and ease operational burden, the
CAP has been slow to attract participants. There have been
legislative and regulatory attempts to modify and improve the
program’s attractiveness and ease of use however the majority of
physicians providing in-ofﬁce drugs continue to do so through
conventional buy and bill methods. Throughout this time the
Medicare drug payment to physician ofﬁces has remained at
average sales price plus six percent (ASP +6%) and the associated
drug administration rates have been fairly stable. CONCLU-
SIONS: The number of providers utilizing the buy and bill
method was expected to decrease following implementation of
the CAP alternative. The CAP program has now been in effect for
over two years, has undergone a number of operational modiﬁ-
cations, and yet continues to experience low enrollment. At this
time it is not possible to determine conclusively the impact of: 1)
inadequate provider incentive to drive the conversion, or 2) the
deterrent effect of remaining program issues. Further investiga-
tion is warranted.
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OBJECTIVES: To identify characteristics of the individual that
may predict pharmaceutical use. We study the impact of socio-
demographic (gender, age, marital status, education, rural/urban
residence) and need factors (chronic diseases, health-related
quality of life, measured by the Greek version of SF-12, previous-
year physician consultations and hospitalizations). METHODS:
Data was obtained from a nationally representative sample
(N = 1005) of the general-non-institutionalized-population in
A366 Abstracts
